Drug
SP-420 clinical trials
Also written SP-420.
Keep track of what changes. Save the SP-420 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- SP-420
- 4
Studies by the year they started
4 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
Pharmacosmos A/S (1) · The University of Texas Health Science Center at San Antonio (1) · Sideris Pharmaceuticals (1) · Abfero Pharmaceuticals, Inc (1)
Studies
Open first, then newest update. How each study uses SP-420 is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic SyndromesRecruitingPhase 2Pharmacosmos A/SNCT05693909Written as SP-420
- Safety of SP-420 in the Treatment of Transfusional Iron OverloadTerminatedPhase 1The University of Texas Health Science Center at San AntonioNCT04741542Written as SP-420
- SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare AnemiasWithdrawnPhase 2Abfero Pharmaceuticals, IncNCT03801889Written as SP-420
- Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-ThalassemiaTerminatedPhase 1Sideris PharmaceuticalsNCT02274233Written as SP-420
Codes
What other systems call SP-420 · ClinicalTrials.gg INT000839
- MeSH (NLM) C000624987SP-420One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624987 | SP-420 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.